Knoa Pharma and GCAR Announce First Newly Diagnosed Glioblastoma Patient Randomized in Phase 2/3 GBM AGILE Evaluation of Tinostamustine and First Recurrent Patient Dosed
Tinostamustine is being studied in newly diagnosed glioblastoma patients who often face limited treatment options STAMFORD, Conn., June 24, 2026 /PRNewswire/ -- Knoa Pharma LLC ("Knoa Pharma"), a public health-focused pharmaceutical company, and the Global Coalition for Adaptive Research...
Tinostamustine is being studied in newly diagnosed glioblastoma patients who often face limited treatment options STAMFORD, Conn., June 24, 2026 /PRNewswire/ -- Knoa Pharma LLC ("Knoa Pharma"), a public health-focused pharmaceutical company, and the Global Coalition for Adaptive Research...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.